Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis-Reference-Cited by-同舟云学术

Association between duration of gonadotrophin‐releasing hormone agonist use and cardiovascular risks: A population‐based competing‐risk analysis

Published:2022-08 Issue:15 Volume:82 Page:1477-1480
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:The Prostate

Author:

Chan Jeffrey S. K.¹^ORCID,Tang Pias¹,Hui Jeremy M. Ho¹,Lee Yan H. A.¹²^ORCID,Dee Edward C.³^ORCID,Ng Kenrick⁴,Liu Kang²,Tse Gary⁵⁶^ORCID,Ng Chi Fai²⁷

Affiliation:

1. Cardio‐Oncology Research Unit, Cardiovascular Analytics Group, Hong Kong China‐UK Collaboration Hong Kong China

2. Division of Urology, Department of Surgery, Faculty of Medicine The Chinese University of Hong Kong Hong Kong China

3. Department of Radiation Oncology Memorial Sloan Kettering Cancer Center New York New York USA

4. Department of Medical Oncology University College London Hospitals NHS Foundation Trust London UK

5. Department of Cardiology, Tianjin Key Laboratory of Ionic‐Molecular Function of Cardiovascular Disease, Tianjin Institute of Cardiology Second Hospital of Tianjin Medical University Tianjin China

6. Kent and Medway Medical School Kent Canterbury UK

7. SH Ho Urology Centre The Chinese University of Hong Kong Hong Kong China

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.24423

Reference11 articles.

1. Diabetes and Cardiovascular Disease During Androgen Deprivation Therapy for Prostate Cancer

2. NCCN Guidelines Insights: Prostate Cancer, Version 1.2021

3. Impact of Hormonal Therapies for Treatment of Hormone-Dependent Cancers (Breast and Prostate) on the Cardiovascular System: Effects and Modifications: A Scientific Statement From the American Heart Association

4. ChanJSK ZhouJ LeeS et al.Fragmented QRS is independently predictive of long‐term adverse clinical outcomes in asian patients hospitalized for heart failure: a retrospective cohort study.Front Cardiovasc Med.2021;1634.doi:10.3389/FCVM.2021.738417

5. WongAYS RootA DouglasIJ et al.Cardiovascular outcomes associated with use of clarithromycin: population based study.BMJ.2016;352.

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PowerAI-Diabetes: Review of glycemic and lipid variability to predict cardiovascular events in Chinese diabetic population;npj Metabolic Health and Disease;2024-07-01

2. Cardiovascular health of patients with cancer: Challenges abound;Trends in Cardiovascular Medicine;2024-04

3. Cardiovascular disease risk assessment and multidisciplinary care in prostate cancer treatment with ADT: recommendations from the APMA PCCV expert network;World Journal of Urology;2024-03-14

4. Cardiovascular disease burden in patients with urological cancers: The new discipline of uro‐cardio‐oncology;Cancer Innovation;2024-02-05

5. Addressing the risk and management of cardiometabolic complications in prostate cancer patients on androgen deprivation therapy and androgen receptor axis-targeted therapy: consensus statements from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology;Frontiers in Oncology;2024-01-31